Literature DB >> 33008590

Characterisation of progestins used in hormonal contraception and progesterone via the progesterone receptor.

Kim Enfield1, Meghan Cartwright2, Renate Louw-du Toit3, Chanel Avenant4, Donita Africander5, Janet P Hapgood6.   

Abstract

Different progestogens are widely used in hormonal therapy and mediate their therapeutic actions via the progesterone receptor (PR). Little published data exist on their relative efficacies and potencies via the PR, while those available may be confounded by off-target receptors, different methodologies and model systems. We performed dose-response analysis to investigate the efficacies and potencies for transcription of progesterone and several progestins widely used in contraception via the B isoform of human PR (PR-B). We compared responses using three different cell lines and two different transient transfection conditions. Results show that in vitro biological responses via PR-B for the select progestogens can vary significantly in biocharacter, rank order and absolute values for efficacies and potencies, depending on the cell line and transfection condition. Progestogen rank orders for published relative binding affinities are mostly different to those for relative efficacies and potencies. These in vitro differences suggest that rank orders and absolute values of the efficacies and potencies of the progestogens are likely to vary in vivo in a cell-specific and progestogen-specific manner, and cannot easily be extrapolated from in vitro data, as is usually the practice. While obtaining such data in vivo is not possible, these in vitro data show proof of concept for likely significant cell- and progestogen-specific PR-B effects.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dose-response; Efficacy; Potency; Progesterone; Progesterone receptor; Progestins

Mesh:

Substances:

Year:  2020        PMID: 33008590      PMCID: PMC8129485          DOI: 10.1016/j.bbrc.2020.09.058

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

1.  Steroid receptor induction of gene transcription: a two-step model.

Authors:  G Jenster; T E Spencer; M M Burcin; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat.

Authors:  Barbara J Attardi; Sailaja Koduri; Sheri A Hild
Journal:  Mol Cell Endocrinol       Date:  2010-06-25       Impact factor: 4.102

3.  CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914.

Authors:  Barbara J Attardi; Janet Burgenson; Sheri A Hild; Jerry R Reel; Richard P Blye
Journal:  Mol Cell Endocrinol       Date:  2002-02-25       Impact factor: 4.102

4.  Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget.

Authors:  Zhiming Zhang; Andrea M Olland; Yuan Zhu; Jeff Cohen; Tom Berrodin; Susan Chippari; Chandrasekaran Appavu; Shen Li; James Wilhem; Raj Chopra; Andrew Fensome; Puwen Zhang; Jay Wrobel; Rayomand J Unwalla; C Richard Lyttle; Richard C Winneker
Journal:  J Biol Chem       Date:  2005-06-03       Impact factor: 5.157

5.  Nortestosterone-derived synthetic progestogens do not activate the progestogen receptor of Murray-Darling rainbowfish (Melanotaenia fluviatilis) but are potent agonists of androgen receptors alpha and beta.

Authors:  Peter A Bain; Anu Kumar; Yukiko Ogino; Taisen Iguchi
Journal:  Aquat Toxicol       Date:  2015-03-31       Impact factor: 4.964

6.  Differential metabolism of clinically-relevant progestogens in cell lines and tissue: Implications for biological mechanisms.

Authors:  Salndave B Skosana; John G Woodland; Meghan Cartwright; Kim Enfield; Maleshigo Komane; Renate Louw-du Toit; Zephne van der Spuy; Chanel Avenant; Donita Africander; Karl-Heinz Storbeck; Janet P Hapgood
Journal:  J Steroid Biochem Mol Biol       Date:  2019-02-26       Impact factor: 4.292

7.  Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.

Authors:  Shinichi Sasagawa; Yutaka Shimizu; Hideaki Kami; Takashi Takeuchi; Shizuka Mita; Kazunori Imada; Shigeaki Kato; Kiyoshi Mizuguchi
Journal:  Steroids       Date:  2007-10-22       Impact factor: 2.668

8.  Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes.

Authors:  Kevin P Madauss; Su-Jun Deng; Robert J H Austin; Millard H Lambert; Iain McLay; John Pritchard; Steven A Short; Eugene L Stewart; Ian J Uings; Shawn P Williams
Journal:  J Med Chem       Date:  2004-06-17       Impact factor: 7.446

9.  Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction.

Authors:  Katharina Ronacher; Katie Hadley; Chanel Avenant; Elisabeth Stubsrud; S Stoney Simons; Ann Louw; Janet P Hapgood
Journal:  Mol Cell Endocrinol       Date:  2008-10-19       Impact factor: 4.102

Review 10.  Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression.

Authors:  Katherine M Scarpin; J Dinny Graham; Patricia A Mote; Christine L Clarke
Journal:  Nucl Recept Signal       Date:  2009-12-31
View more
  3 in total

Review 1.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

2.  Differential off-target glucocorticoid activity of progestins used in endocrine therapy.

Authors:  Maleshigo Komane; Chanel Avenant; Renate Louw-du Toit; Donita J Africander; Janet P Hapgood
Journal:  Steroids       Date:  2022-03-07       Impact factor: 2.760

3.  Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation.

Authors:  Marie Shamseddin; Fabio De Martino; Céline Constantin; Valentina Scabia; Anne-Sophie Lancelot; Csaba Laszlo; Ayyakkannu Ayyannan; Laura Battista; Wassim Raffoul; Marie-Christine Gailloud-Matthieu; Philipp Bucher; Maryse Fiche; Giovanna Ambrosini; George Sflomos; Cathrin Brisken
Journal:  EMBO Mol Med       Date:  2021-05-27       Impact factor: 12.137

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.